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ABSTRACT 
Background and Objectives: Several studies have shown that angiotensin II receptor blockers (ARBs) improve 
endothelial function and arterial stiffness. Telmisartan is a highly selective ARB that activates peroxisome 
proliferator-activated receptor γ (PPARγ). The purpose of this study was to evaluate the effects of telmisartan, 
such as endothelial function, arterial stiffness, and insulin sensitivity, in patients with essential hypertension. 
Subjects and Methods: Thirty-nine patients with essential hypertension were administered telmisartan (80 mg 
once daily) using an open-labeled and prospective protocol. The patients were examined before and 8 weeks 
after treatment to assess changes in flow mediated-vasodilation (FMD), pulse wave velocity (PWV), quantitative 
insulin-sensitivity check index (QUICKI), homeostasis model assessment (HOMA), and adiponection. Results: 
The systolic and diastolic blood pressure (BP) decreased from 153±15 mmHg and 90±13 mmHg to 137±16 
mmHg and 84±10 mmHg after telmisartan treatment, respectively (p<0.01). Telmisartan therapy increased the 
FMD from 7.6±3.5 to 9.0±2.8% (p<0.01). The following parameters of arterial stiffness were significantly 
improved after telmisartan therapy: brachial-ankle pulse wave velocity (baPWV), from 17.2±3.1 to 15.9±2.6 m/ 
sec; heart-carotid PWV (hcPWV), from 9.7±1.8 to 9.0±1.9 m/sec; and heart-femoral PWV (hfPWV), from 
11.3±1.9 to 10.7±1.9 m/sec (p<0.01). There were no changes in QUICKI, the HOMA level, and plasma adi-
ponectin (p=NS). Conclusion: These results suggest that telmisartan is effective in improving endothelial function 
and arterial stiffness in patients with essential hypertension. (Korean Circ J 2009;39:180-184) 
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Introduction 
 
Hypertension is accompanied by vascular endothelial 
dysfunction, the underlying etiology of atherosclerosis, 
and hypertension is closely associated with metabolic 
disorders, such as obesity and type 2 diabetes mellitus, 
which are caused by insulin resistance.
1) 
The function of vascular endothelial cells is measured 
by flow-mediated, endothelium-dependent vasodilation 
(FMD) of the forearm. Vascular endothelial cells are 
examined and serve as useful indicators in the diagnosis 
and treatment of atherosclerosis and cardiovascular di-
seases. In patients who have risk factors for developing 
cardiovascular diseases, such as hypertension and dia-
betes, it is also well-known that dysfunction of vascular 
endothelial cells occurs due to the decreased vasodilation 
response.
2) Arterial stiffness is also an indicator that can 
be used to predict cardiovascular risk factors. In recent 
years, measurement of the pulse wave velocity (PWV) has 
frequently been performed to predict major cardiovas-
cular events.
3)4) Because arterial stiffness is increased in 
patients with hypertension, the PWV is decreased, i.e., 
the improvement in arterial stiffness is used to determine 
the additional effects of anti-hypertensive drugs.
5)6) 
Previous studies have shown that angiotensin con-
verting enzyme (ACE) inhibitors or statins have a vaso-
dilatory effect based on the improvement in vascular 
endothelial function.
6-8) It has also been reported that 
some angiotensin II type 1 receptor blockers (ARBs) 
improve vascular endothelial function by activation of 
peroxisome proliferator-activated receptor  γ (PPARγ) 
via anti-inflammatory action and an anti-oxidative effect. 
Furthermore, ARBs have also been reported to elevate 
adiponectin, which is associated with an improvement 
in insulin resistance.
9-12) In Korea, however, few studies 
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have examined the effects of ARBs and telmisartan on 
vascular endothelial function, arterial stiffness, and in-
sulin sensitivity.
12)21)26) 
In the current study, we examined the effects of ARB 
and telmisartan on vascular endothelial function, arterial 
stiffness, and insulin resistance in patients with essential 
hypertension.  
 
Subjects and Methods 
 
Patients 
The current study was conducted in 39 patients with 
less than severe hypertension (systolic pressure <180 
mmHg or diastolic pressure <110 mmHg) who were eval-
uated in the Department of Cardiology of our hospital. 
These patients consisted of 36 men and 3 women, with 
a mean age of 61±6 years. The current study was ap-
proved by the Institutional Review Board (IRB) of our 
hospital. All of the patients were given a full explana-
tion of the study objectives before signing a written in-
formed consent. Exclusion criteria were severe hyper-
tension, acute coronary syndrome, cardiac failure, renal 
failure, liver cirrhosis, and uncontrolled diabetes {hemo-
globin A1c (HbA1c) >10.0%}. 
At the time of the baseline visit, the patients under-
went the following laboratory tests: general blood test, 
serum biochemistry, EKG, chest radiography, and uri-
nalysis. Following a 2-week screening period, the cur-
rent study was initiated. Following a 2-week wash-out 
period in patients who were taking anti-hypertensive 
drugs, such as statins or ARBs, and after the screening 
period, telmisartan (80 mg) was administered. Prior to 
the administration and at week 8, blood tests, FMD, 
PWV, and indices of insulin resistance, such as quan-
titative insulin sensitivity check index (QUICKI) and ho-
meostasis model assessment (HOMA and adiponectin), 
were compared. 
 
Blood pressure measurement 
For blood pressure measurement, stabilization was 
attempted for >10 minutes and the blood pressure was 
measured 2 times at a minimum interval of 10 minutes 
in the right forearm in a sitting position. Then, the 
measurements were averaged. Cases in which the systolic 
pressure was >140 mmHg or the distolic pressure was 
>90 mmHg were defined as hypertension. 
 
The evaluation of vascular endothelial function 
The evaluation of vascular endothelial function was 
performed by FMD, a non-invasive method. After an 
more than 8-hour fast, patients were stabilized in the 
supine position in a quiet place where the indoor tem-
perature was maintained at 22-23℃ and the inferior 
part of their right forearm was placed in a blood pres-
sure cuff. Following this, the FMD measurement was per-
formed. To assure that the ultrasonographic findings of 
the humeral artery were detected, the most accessible 
area which was 2-5 cm inferior to the antecubital fossa 
was targeted by a high-resolution ultrasonography unit 
(Sequoia 512; Acuson, USA), to which a 10 MHz linea-
rarray transducer was implanted, and ultrasonography 
was performed according to the methods that have been 
reported in a prior publication.
13)14) The baseline diam-
eter of the brachial artery was measured, and the pressure 
of a barometer which surrounded the arm was elevated 
to 200 mmHg. The blood flow in the brachial artery was 
blocked for 5 minutes. Then, the pressure was abruptly 
dropped to 0 mmHg and the vasodiliatory response was 
measured 3 times for 1 minute. In measuring the dia-
meter of the blood vessels, the homogeneous images of 
the intima could not be obtained. The distance bet-
ween the media, corresponding to the tunica media, 
was alternatively measured. To minimize the error in 
the measurements, the possible baseline point was es-
tablished in the areas where the arterial branch was 
placed. The time point of measurement was the end-
point of the diastole phase. Thus, the diameter was 
measured immediately before the initial part of the R 
wave on the EKG. Following the analysis of the change 
in diameter, using the diameter which was maximally 
extended, the increased diameter compared to the base-
line measurement was calculated as a percentile value 
(%). Thus, the degree of vasodilation was obtained {F-
MD %=(maximum dilated diameter-baseline diameter)/ 
baseline diameter×100}. 
 
Insulin sensitivity and adiponectin measurement 
Blood sampling was done in the morning prior to the 
treatment and following 8-week of drug administration 
an more than 8-hour fasting. Plasma insulin was meas-
ured with a radioimmunoassay (RIA; Biosource Inc., 
Nivelles, Belgium) and adiponectin was measured with 
a RIA (LINCO Research Inc., Missouri, USA). Indices 
for insulin sensitivity (QUICKI and HOMA) were cal-
culated based on the following formula: QUICKI=1/ 
{log (insulin)+log (glucose)} and HOMA=fasting in-
sulin×fasting glucose/22.5. 
The units of insulin and glucose were  μU/mL and 
mg/dL, respectively.
15) 
 
Measurement of the pulse wave velocity 
PWV was measured based on conventional methods 
with the use of autowave form analysis (VP-2000; Colin 
Medical Technology Co., Komaki, Japan) in a fasting 
state following stabilization of the heart rate.
16) The pulse 
wave velocity between the bilateral brachial arteries and 
the ankle (ba) was measured by placing both arms and 
the ankle in a cuff, to which an oscillometric sensor was 
implanted. A tonometric sensor was placed in the heart-
femoral (hf) and the heart-carotid (hc) for recording.  
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Follow-up test 
During the trial, the occurrence of side effects was con-
firmed by physical examination, as well as hematologic 
measures. 
 
Statistical analysis 
All data are expressed as the mean±SD. A compari-
son of the measurements prior to and following admin-
istration was made using a paired t-test. All the statis-
tical procedures were performed using Statistical Package 
for Social Science (SPSS) 13.0 (SPSS Inc., Chicago, IL, 
USA). A p<0.05 was considered statistically significant. 
 
Results 
 
Of 42 patients who took drugs for 8 weeks, 39 patients 
had a follow-up visit. Of the three patients who were 
dropped from the current analysis, two did not visit the 
outpatient clinic and the remaining patient declined to 
take the test. The subject patients consisted of 36 males 
and 3 females, with a mean age of 61±6 years (Table 1). 
Twelve patients had type 2 diabetes mellitus. In these 
patients, the mean weight was 69.8±8.2 kg and the 
body mass index (BMI) was 24.7±2.4 gm/m
2. Neither 
hypotension nor hyperkalemia occurred in any of the 
patients. Likewise, discontinuation of drug treatment did 
not occur. In the subject patients, the sitting position 
blood pressure was measured following the administra-
tion of telmisartan. This showed that the systolic pres-
sure was significantly decreased from 153±15 mmHg 
to 137±16 mmHg (p<0.01) and the diastolic pressure 
was significantly decreased from 90±13 mmHg to 
84±10 mmHg (p<0.01; Fig. 1). On blood testing, there 
were no significant differences in cholesterol, triglyce-
rides, and low-density lipoprotein- cholesterol. The con-
centration of high-density lipoprotein cholesterol was 
significantly increased (51±12 vs. 53±17 mg/dL, p< 
0.01). However, there were no significant differences in 
high sensitivity C-reactive protein (hs-CRP) (1.9±2.9 vs. 
1.8±2.5 mg/dL, p=NS), hemoglobin A1c (HbA1c) 
(6.4±1.0 vs. 6.3±1.2%, p=NS), and N-terminal pro-
B-type natriuretic peptide (NT-proBNP)  (39.1±45.2 
vs. 26.7±26.6 pg/dL, p=0.063; Table 1). 
Vasodilatory responses were improved from 7.6± 
3.5% at baseline to 9.0±2.8% following the admin-
istration of telmisartan (p<0.01; Fig. 2). The PWV was 
significantly decreased prior to the administration of 
telmisartan and following the administration of tel-
misartan between the bilateral brachial and ankle artery 
and between the heart and the carotid artery (Table 2). 
However, there were no significant difference in QUIC-
KI (0.36±0.04 vs. 0.37±0.04, p=0.083), HOMA (2.16 
±1.63 vs. 1.78±1.33, p=NS), and adiopnectin (7116.3 
±2379.8 vs. 7795.6±3815.7 μg/mL, p=NS). 
Table 1. Baseline and follow-up characteristics of the subjects
  Baseline  After 8 weeks  p 
Age (years)  61±60  
Male: Female  36 : 3  
Smoker (%)  53.8   
Smoking history (PYS)  22.7±14.1  
Body mass index (gm/m
2) 24.7±2.40  
Glucose (mg/dL)  109±280  112±410 NS 
HbA1c (%)  6.4±1.0 6.3±1.2 NS 
Total cholesterol (mg/dL)  208±330  206±320 NS 
Triglycerides (mg/dL)  190±105  163±760 0.113 
HDL-C (mg/dL)  51.1±11.8  53.4±17.4.  <0.01 
LDL-C (mg/dL)  136.2±28.10  137.1±32.0.  NS 
hs-CRP (mg/L)  1.95±2.86 1.78±2.54  NS 
NT-proBNP (pg/mL)  39.1±45.2 26.7±26.6  0.063 
Adiponectin (μg/mL) 7.1±2.4 7.8±3.8 NS 
QUICKI 0.36±0.04 0.37±0.04  0.083 
HOMA 2.16±1.63 1.78±1.33  NS 
HDL-C: high-density lipoprotein- cholesterol, LDL-C: low-density
lipoprotein- cholesterol, hs-CRP: high sensitivity C-reactive protein,
NT-proBNP: N-terminal proBNP, QUICKI: quantitative insulin
sensitivity check index, HOMA: homeostasis model assessment   
Fig. 1. Effects of telmisartan on systolic and diastolic blood pres-
sure (BP). P<0.05 vs. baseline value. 
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Fig. 2. Change of flow mediated-dilation (FMD) at baseline and 
8 weeks after telmisartan treatment. P<0.01 vs. baseline value. 
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Discussion 
 
In the current study, telmisartan was administered at 
a dose of 80 mg/day for 8 weeks in patients with es-
sential hypertension. It was shown that the sitting systolic 
and diastolic pressures were significantly decreased and 
the function of vascular endothelial cells and arterial 
stiffness were improved. 
It has been well-demonstrated that angiotension II 
plays a crucial role in the gradual progression of tissue 
injury and atherosclerosis in structures, such as blood 
vessels, kidneys, heart, and brain.
10) There exists an abun-
dance of results regarding the long-term protective effect 
of ARBs in inhibiting the activity of angiotensin II. 
According to the ONTARGET study, the results of which 
have been reported in recent years, ARBs have been 
demonstrated to have a preventive effect for cardiovas-
cular events equivalent to ramipril.
17) Presumably, these 
results might be due to the very strong activity of PPARγ 
as well as the high histocompatibility and very long half-
life of telmisartan.
17)18) 
Vascular endothelial cells are mainly responsible for 
the progression of atherosclerosis and the regulatory 
process of vascular stiffness, which are known to be dam-
aged by various risk factors of developing atheroscle-
rosis.
2) Some authors have attempted to improve the 
function of vascular endothelial cells with the use of 
anti-hypertensive drugs. Accordingly, it has been shown 
that ACE inhibitors and ARBs increase the endothe-
lium-dependent vasodilatory responses.
2)10)19) It has also 
been reported that ARBs suppress the arterial damage 
and the atherosclerotic progression due to hypercholes-
terolemia and hypertension.
20) In the current study, it 
was first demonstrated that the administration of tel-
misartan (80 mg) significantly increased the vasodilatory 
response during an 8-week period in Korea. It can even-
tually be inferred that the administration of telmisartan 
will have an affirmative effect on the progression of ath-
erosclerosis due to the improvement of vascular endo-
thelial functions. These findings are in agreement with 
the report of Cho et al.,
19) which showed that ramipril 
had a short-term effect on the improvement of vascular 
endothelial function. The inhibition of the activation of 
the renin-angiotensin system can be considered as the 
key mechanism by which atherosclerotic progression is 
suppressed. In the current study, however, the effect of 
the long-term administration of telmisartan remains 
unclear. Because the current study was conducted in the 
absence of a control group, it was also unclear whether 
the vascular endothelial function were improved by the 
anti-hypertensive effect or occurred as a result of the drug 
effect itself. Considering the previous studies conducted 
by Koh et al. showing that pioglitazone (a PPARγ ac-
tivator) improved the function of vascular endothelial 
cells in patients with metabolic syndrome; however, it is 
assumed that the effect of telmisartan itself could not be 
completely ruled out.
11)12) 
With respect to the metabolic effect, it has been shown 
that ARBs have a positive effect on the occurrence of 
diabetes mellitus by increasing the insulin-mediated ab-
sorption of glucose, stimulating adipogenesis, inducing 
the differentiation of adipocytes, and activating PPARγ. 
This has also been demonstrated in a large-scale clinical 
trial.
22) This effect has been reported to have a relation-
ship with the activation of PPARγ  with no association 
to the degree of blocking of the angiotension II type 1 
receptor.
23) In particular, telmisartan has the most pow-
erful effect in activating PPARγ. Accordingly in the 
current study, the effect of telmisartan on insulin sen-
sitivity was expected. Indices for insulin sensitivity, in-
cluding QUICKI, HOMA, and adiponectin, were meas-
ured. This showed that the administration of telmis-
artan did not improve insulin sensitivity. Presumably, 
this might be because a majority of the subject patients 
included patients with hypertension who were different 
from those with metabolic syndrome or diabetes mellitus 
and who concurrently had a severe metabolic disorder. 
A rigorous management of diet and exercise therapy was 
not simultaneously instituted. The current study was 
conducted during a relatively short, 8-week period. De-
spite a lack of statistical significance, however, the overall 
parameters were improved. A persistent treatment would 
therefore produce more positive outcomes. 
It is generally known that all the anti-hypertensive 
drugs do not reduce arterial stiffness. Calcium blockers 
or ACE inhibitors are known to be effective in this series. 
In the current study, arterial stiffness was significantly 
reduced. This was greatly different from the previous 
studies, conducted by Rhee at al.,
6) reporting that stiffness 
of the aorta was not improved by the administration of 
losartan. Presumably, this might be due to the differences 
in the patient group or the administration dose {losartan 
(50 mg) vs. telmisartan (80 mg)}. As compared with the 
previous small-scale studies which were conducted using 
ARBs in patients with essential hypertension, despite 
the differences in the period of drug administration, 
dose, the number of enrolled patients, and the type of 
concomitant drugs, the current study showed that the 
vasodilatory responses, PWV, and insulin resistance were 
significantly improved or showed a tendency toward im-
provement.
6)24-26) The results of the current study cannot 
Table 2. Effects of telmisartan on pulse wave velocity 
  Baseline  After 8 weeks 
Right baPWV (m/sec)  17.21±3.13 15.93±2.64
† 
Left baPWV (m/sec)  17.38±2.82 16.04±2.57
† 
Hc PWV (m/sec)  09.74±1.85  09.02±1.95
† 
Hf PWV (m/sec)  11.34±1.98 10.73±1.99* 
*p<0.05,  †p<0.01 vs. baseline value. ba: brachial-aorta, Hc: heart-
carotid, Hf: heart-femoral, PWV: pulse wave velocity 
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be understated, but it can be inferred that telmisartan 
has its own effect on the improvement of vascular endo-
thelial functions and arterial stiffness from the aspect of 
the class effects of angiotension II inhibitors and insulin 
sensitivity. 
The limitations of the current study were as follows: 
1) The current study was conducted in a relatively 
small number of enrolled patients, and it was conducted 
in the absence of a control group. Further large-scale 
studies are therefore warranted to obtain more significant 
results. 
2) The current study was conducted without a rigorous 
management of living habits, such as exercise or dietary 
habit. Blood glucose control or laboratory results might 
affect the results of the current study. During the con-
duct of a trial, however, the types of drugs were not 
changed. The changes in the functions of vascular en-
dothelial cells or PWV might originate from the addi-
tional effects of ARB rather than their anti-hypertensive 
ones, as shown in other studies.
10)27) 
In conclusion, the short-term administration of tel-
misartan significantly improved the functions of vascular 
endothelial cells and the arterial stiffness in patients 
with less than severe essential hypertension. But insulin 
sensitivity was not improved. 
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